Inflarx N.V. (IFRX) — 6-K Filings

6-K Filings (29)

• InflaRx N.V. Files 6-K Report — Apr 23, 2026 Risk: low
  InflaRx N.V. filed a Form 6-K on April 23, 2026, reporting as a foreign issuer. The filing includes a 6-K document, an exhibit (EX-99.1), and a graphic image. T
• InflaRx N.V. Files Form 6-K — Apr 9, 2026 Risk: low
  InflaRx N.V. filed a Form 6-K on April 9, 2026, reporting as a foreign issuer. The filing includes a press release dated April 9, 2026, and associated graphic f
• InflaRx Updates Vilobelimab Phase 3 Data After Trial Termination — Dec 30, 2025 Risk: medium
  On December 30, 2025, InflaRx N.V. provided an update on Phase 3 data analyses for its drug vilobelimab in treating pyoderma gangrenosum. This follows the earli
• 6-K Filing — Nov 10, 2025
• InflaRx N.V. Faces Nasdaq Bid Price Non-Compliance — Sep 12, 2025 Risk: medium
  InflaRx N.V. filed a 6-K on September 12, 2025, to update on its non-compliance with Nasdaq's minimum bid price requirement. The company was notified on July 11
• InflaRx N.V. Files 6-K, Incorporates Exhibits — Aug 7, 2025 Risk: low
  InflaRx N.V. filed a Form 6-K on August 7, 2025, reporting information for the month of August 2025. This filing includes exhibits 99.1 and 99.2, which are inco
• InflaRx Faces Nasdaq Delisting Threat Over Low Share Price — Jul 14, 2025 Risk: high
  InflaRx N.V. received a written notice from Nasdaq on July 11, 2025, stating that its ordinary shares have closed below the $1.00 minimum bid price requirement
• InflaRx N.V. Changes Independent Auditor to KPMG — Jun 27, 2025 Risk: low
  On June 26, 2025, InflaRx N.V. announced a change in its independent registered public accounting firm. The company has engaged KPMG AG Wirtschaftsprüfungsgesel
• InflaRx Halts Phase 3 Trial for Vilobelimab Due to Futility — May 28, 2025 Risk: high
  On May 28, 2025, InflaRx N.V. announced that the Independent Data Monitoring Committee recommended stopping their Phase 3 trial for vilobelimab in pyoderma gang
• InflaRx N.V. Files 6-K for Registration Statement Incorporation — May 7, 2025 Risk: low
  InflaRx N.V. filed a Form 6-K on May 7, 2025, to incorporate by reference Exhibits 99.1 and 99.2 into its existing registration statements on Form S-8 (File Nos
• InflaRx N.V. Reports 2024 Annual Meeting Results — Apr 24, 2025 Risk: low
  InflaRx N.V. held its Annual General Meeting of Shareholders on April 24, 2025. The primary agenda item was the adoption of the Dutch statutory annual accounts
• InflaRx N.V. Announces Annual Shareholder Meeting — Apr 3, 2025 Risk: low
  InflaRx N.V. filed a Form 6-K on April 3, 2025, to announce its annual general meeting of shareholders scheduled for April 24, 2025. The company made certain ma
• InflaRx N.V. Reports 2024 Results and Milestones — Mar 20, 2025 Risk: low
  On March 20, 2025, InflaRx N.V. (the "Company") issued a press release reporting its full-year 2024 results and highlighting key achievements and expected miles
• InflaRx N.V. Files 6-K for Share Offering — Feb 18, 2025 Risk: medium
  On February 13, 2025, InflaRx N.V. entered into an Underwriting Agreement with Guggenheim Securities, LLC, as representative of the underwriters, for an offerin
• InflaRx N.V. Gets EU Approval for GOHIBIC® for ARDS — Jan 15, 2025 Risk: medium
  On January 15, 2025, InflaRx N.V. announced that the European Commission has granted marketing authorization under exceptional circumstances for GOHIBIC® (vilob
• InflaRx Doses First Patient in INF904 Phase 2a Study — Dec 20, 2024 Risk: medium
  On December 20, 2024, InflaRx N.V. announced that the first patient has been dosed in its Phase 2a basket study for its oral C5aR inhibitor, INF904. This multi-
• InflaRx N.V. Gets Positive CHMP Opinion for GOHIBIC® — Nov 15, 2024 Risk: medium
  On November 15, 2024, InflaRx N.V. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a posit
• InflaRx N.V. Files 6-K, Incorporates Exhibits — Nov 8, 2024 Risk: low
  InflaRx N.V. filed a Form 6-K on November 8, 2024, to incorporate by reference certain exhibits into its existing registration statements on Form S-8 and Form F
• InflaRx Files 6-K, Incorporates Exhibits into S-8 Filings — Aug 8, 2024 Risk: low
  InflaRx N.V. filed a Form 6-K on August 8, 2024, reporting information for the month of August 2024. The filing includes exhibits 99.1 and 99.2, which are incor
• InflaRx N.V. Launches At-The-Market Share Offering — Jun 28, 2024 Risk: medium
  On June 28, 2024, InflaRx N.V. entered into a Sales Agreement with Leerink Partners LLC to conduct an "at-the-market" offering of its ordinary shares. This agre
• InflaRx's GOHIBIC Tapped for BARDA ARDS Trial — Jun 24, 2024 Risk: medium
  On June 24, 2024, InflaRx N.V. announced that its GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development Authority (BARDA)
• InflaRx N.V. Highlights Promise of INF904 at R&D Event — Jun 5, 2024 Risk: low
  On June 5, 2024, InflaRx N.V. hosted a virtual R&D event to highlight the potential of its drug candidate INF904. The company presented its corporate presentati
• InflaRx N.V. Presents COVID-19 Trial Synergy Data — May 21, 2024 Risk: medium
  On May 21, 2024, InflaRx N.V. announced new analysis from its PANAMO Phase III trial for severe COVID-19. The analysis suggests potential synergy between their
• InflaRx N.V. 6-K Filing Incorporates Exhibits — May 8, 2024 Risk: low
  InflaRx N.V. filed a Form 6-K on May 8, 2024, to report information for the month of May 2024. The filing indicates that Exhibits 99.1 and 99.2 are incorporated
• InflaRx N.V. Approves 2023 Annual Accounts — Apr 25, 2024 Risk: low
  InflaRx N.V. held its Annual General Meeting of Shareholders on April 25, 2024. Shareholders approved the adoption of the Dutch statutory annual accounts for th
• InflaRx N.V. Announces Annual Shareholder Meeting — Apr 4, 2024 Risk: low
  InflaRx N.V. filed a Form 6-K on April 4, 2024, to announce its annual general meeting of shareholders scheduled for April 25, 2024. The company also made certa
• InflaRx Reports 2023 Results, Pipeline Updates — Mar 21, 2024 Risk: medium
  On March 21, 2024, InflaRx N.V. reported its full-year 2023 financial and operating results. The company provided updates on its immuno-dermatology pipeline, sp
• InflaRx Launches GOHIBIC Commitment Program to Broaden Patient Access — Jan 25, 2024
  InflaRx N.V. (Nasdaq: IFRX) announced on January 25, 2024, the initiation of "The InflaRx Commitment Program" for its drug GOHIBIC® (vilobelimab). This program
• InflaRx INF904 Phase I Study Shows Positive Topline Results — Jan 4, 2024
  InflaRx N.V. announced positive topline results on January 4, 2024, from its Multiple Ascending Dose (MAD) Phase I study for C5aR inhibitor INF904. The study, w

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX